Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07219940
PHASE1

A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects

Sponsor: Shine-On Biomedical Co., Ltd.

View on ClinicalTrials.gov

Summary

The investigational drug, SOB100, is an HLA-G targeted exosome equipped with a nanobody namely anti-HLA-G VHH on the exosome membrane. This is a Phase I dose escalation study to exam the tolerability, safety, and pharmacokinetics in healthy subjects.

Official title: An Open-label and Dose-escalation Phase I Clinical Study to Evaluate the Tolerability, Safety, and Pharmacokinetics of HLA-G-targeted Exosome (SOB100) in Healthy Subjects

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

15

Start Date

2025-12-01

Completion Date

2027-03

Last Updated

2026-01-26

Healthy Volunteers

Yes

Interventions

DRUG

SOB100

Drug: SOB100 Participants will receive SOB100 and evaluate the safety and tolerability of SOB100 during the dose escalation phase.

Locations (1)

Parexel International - Baltimore Early Phase Clinical Unit

Baltimore, Maryland, United States